Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical and Experimental Nephrology|June 27, 2007
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney diseaseSeiji Ueda, Sho-Ichi Yamagishi, Yuriko Matsumoto, et al.
Molecular Medicine (Cambridge, Mass.)|November 8, 2006
Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failureSeiji Ueda, Sho-ichi Yamagishi, Masayoshi Takeuchi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 19, 2008
Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathyRyo Shibata, Seiji Ueda, Sho-Ichi Yamagishi, et al.
Journal of the American Society of Nephrology : JASN|June 30, 2006
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney diseaseKyoko Matsuguma, Seiji Ueda, Sho-ichi Yamagishi, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 2, 2008
Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected ratsToshiko Fujimura, Sho-ichi Yamagishi, Seiji Ueda, et al.
Pageof 1